Dr. Becerra Discusses Regorafenib Dosing in Metastatic CRC

Carlos Becerra, MD
Published: Monday, Aug 20, 2018



Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer (mCRC).

The phase II ReDOS study of regorafenib in patients with mCRC demonstrated that a weekly dose-escalation schedule of the oral multikinase inhibitor was superior to the previously standard starting dose of 160 mg. The findings from this trial led to the NCCN changing their guidelines on the use of regorafenib in this patient population.

Becerra says that this is a very difficult population to treat, as their disease is highly resistant. Before ReDOS, patients who were started at the standard 160 mg dose often had to pause or discontinue treatment due to the toxicities. One of the questions going into ReDOS was whether starting at a lower dose would still deliver the same benefit. ReDOS showed that starting at 80 mg, observing the tolerance, and then escalating if appropriate, led to a dramatic increase in overall survival, Becerra says.


Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer (mCRC).

The phase II ReDOS study of regorafenib in patients with mCRC demonstrated that a weekly dose-escalation schedule of the oral multikinase inhibitor was superior to the previously standard starting dose of 160 mg. The findings from this trial led to the NCCN changing their guidelines on the use of regorafenib in this patient population.

Becerra says that this is a very difficult population to treat, as their disease is highly resistant. Before ReDOS, patients who were started at the standard 160 mg dose often had to pause or discontinue treatment due to the toxicities. One of the questions going into ReDOS was whether starting at a lower dose would still deliver the same benefit. ReDOS showed that starting at 80 mg, observing the tolerance, and then escalating if appropriate, led to a dramatic increase in overall survival, Becerra says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x